Keywords
Stem cells
Ofatumumab
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To compare the effectiveness and applicability of treatments with monoclonal antibodies and stem cell therapy in patients with Multiple Sclerosis, through a systematic literature review. Methods: The research was conducted based on a meticulous analysis of literature published in the PubMed and Cochrane databases, with publications from the last five years. The descriptors used included: "Multiple Sclerosis," "Monoclonal Antibodies," "Ofatumumab," and "Stem Cells." Results: The analysis indicates that the investigated therapies demonstrate significant therapeutic potential. Monoclonal antibodies prove promising in reducing disability progression and decreasing relapse rates. In the context of stem cell therapies, autologous hematopoietic stem cell transplantation stands out with promising results in immune modulation and neuroprotection. Nevertheless, challenges persist in defining treatment guidelines due to the scarcity of direct comparative studies between the approaches. Final considerations: The studied therapeutic modalities are of utmost relevance for the treatment of Multiple Sclerosis. The selection of the appropriate therapy requires individual analysis, considering specific patient characteristics and the disease profile. The establishment of guidelines is imperative, particularly in evaluating benefits and applicability for each expression of Multiple Sclerosis.
References
BAR-OR A, et al. Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study. Multiple Sclerosis Journal, 2022; 28(6): 910-924.
BAYAS A, et al. Disease-modifying therapies for relapsing/active secondary progressive multiple sclerosis–a review of population-specific evidence from randomized clinical trials. Therapeutic Advances in Neurological Disorders, 2023; 16: 17562864221146836.
BERARD JA, et al. Mesenchymal stem cell therapy and cognition in MS: Preliminary findings from a phase II clinical trial. Multiple Sclerosis and Related Disorders, 2022; 61: 103779.
BRITTAIN G, et al. Efficacy and safety of autologous haematopoietic stem cell transplantation versus alemtuzumab, ocrelizumab, ofatumumab or cladribine in relapsing remitting multiple sclerosis (StarMS): protocol for a randomised controlled trial. BMJ open, 2024; 14(2): e083582.
COHEN J, et al. Effect of longer-term ofatumumab treatment on disability progression and brain volume change (S16. 009). Neurology, 2023; 100(17): 2421.
HARRIS VK, et al. Mesenchymal stem cell-derived neural progenitors in progressive MS: Two-year follow-up of a phase I study. Neurology: Neuroimmunology & Neuroinflammation, 2020; 8(1): e928.
HARRIS VK, et al. Efficacy of intrathecal mesenchymal stem cell-neural progenitor therapy in progressive MS: results from a phase II, randomized, placebo-controlled clinical trial. Stem Cell Research & Therapy, 2024; 15(1): 151.
HAUSER SL, et al. Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years. Multiple Sclerosis Journal, 2022; 28(10): 1576-1590.
HENDRAWAN K, et al. Long-term suppression of circulating proinflammatory cytokines in multiple sclerosis patients following autologous haematopoietic stem cell transplantation. Frontiers in Immunology, 2022; 12: 782935.
JAMALI F, et al. Human Umbilical Cord–Derived Mesenchymal Stem Cells in the Treatment of Multiple Sclerosis Patients: Phase I/II Dose-Finding Clinical Study. Cell Transplantation, 2024; 33: 09636897241233045.
KRÅKENES T, et al. The neuroprotective potential of mesenchymal stem cells from bone marrow and human exfoliated deciduous teeth in a murine model of demyelination. PloS one, 2023; 18(11): e0293908.
MARIOTTINI A, et al. Should autologous hematopoietic stem cell transplantation be offered as a first-line disease modifying therapy to patients with multiple sclerosis?. Multiple Sclerosis and Related Disorders, 2023; 78: 104932.
NABAVI SM, et al. Intravenous transplantation of bone marrow-derived mesenchymal stromal cells in patients with multiple sclerosis, a phase I/IIa, double blind, randomized controlled study. Multiple Sclerosis and Related Disorders, 2023; 78: 104895.
PARDO G, et al. Longer-term (Up to 6 Years) Efficacy of Ofatumumab in People with Recently Diagnosed and Treatment-naive Relapsing Multiple Sclerosis (S31. 003). In: Neurology. Hagerstown, MD: Lippincott Williams & Wilkins, 2024; 6149.
PETROU P, et al. Beneficial effects of autologous mesenchymal stem cell transplantation in active progressive multiple sclerosis. Brain, 2020; 143(12): 3574-3588.
PETROU P, et al. Effects of mesenchymal stem cell transplantation on cerebrospinal fluid biomarkers in progressive multiple sclerosis. Stem Cells Translational Medicine, 2022; 11(1): 55-58.
SOUZA MT, et al. Revisão integrativa: o que é e como fazer. Einstein (São Paulo), 2010; 8: 102-106.
TREMBLAY F, et al. Neurophysiological outcomes following mesenchymal stem cell therapy in multiple sclerosis. Clinical Neurophysiology, 2022; 136: 69-81.
UCCELLI A, et al. Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial. The Lancet Neurology, 2021; 20(11): 917-929.
VISWESWARAN M, et al. Sustained immunotolerance in multiple sclerosis after stem cell transplant. Annals of Clinical and Translational Neurology, 2022; 9(2): 206-220.
WIENDL H, et al. Longer-term Safety and Efficacy of Ofatumumab in People with Relapsing Multiple Sclerosis for Up to 6 Years (P9-6.010). In: Neurology. Hagerstown, MD: Lippincott Williams & Wilkins, 2024; 5101.